Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.36 |
| ▸ | TOP1 | P11387 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605307 | 0.79 | KDM4E (0.40) | ESR1ESR2KDM4EGAACYP19A1 | |
| SCHEMBL4273017 | 0.72 | CYP19A1 (0.44) | ESR1ESR2CYP19A1MAPTGPR84 | |
| SCHEMBL4942284 | 0.71 | TOP1 (0.37) | KDM4EGAATOP1GPR84FFAR1 | |
| SCHEMBL26011404 | 0.71 | ESR2 (0.35) | ESR1ESR2MAPTGPR84FFAR1 | |
| SCHEMBL4267427 | 0.70 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL8745832 | 0.69 | DAGLA (0.37) | TOP1GPR84FFAR1 | |
| SCHEMBL4269527 | 0.68 | CYP19A1 (0.37) | ESR1ESR2CYP19A1MAPT | |
| SCHEMBL1018909 | 0.64 | GPR84 (0.45) | KDM4EMAPTGPR84FFAR1 | |
| SCHEMBL21556783 | 0.63 | TP53 (0.56) | GPR84FFAR1 | |
| SCHEMBL5178494 | 0.63 | TP53 (0.56) | GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003706-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME | MEIJI MILK PROD CO LTD (JP) | 2003-03-05 | — | — | EP | claimed |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | MEIJI CO., LTD (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | PMP22, NGF, HRH1 | ESR1 4498/4885ESR2 3563/4885KDM4E 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.